XyloCor Therapeutics
Focused on the development of novel gene therapy for unmet needs in advanced coronary artery disease.
| Date | Investors | Amount | Round |
|---|---|---|---|
| investor investor | €0.0 | round | |
| investor investor | €0.0 | round | |
| investor investor investor investor investor | €0.0 | round | |
* | $67.5m | Series B | |
| Total Funding | 000k | ||
Related Content
XyloCor Therapeutics is a biotechnology company dedicated to enhancing the lives of individuals suffering from cardiovascular disease through the advancement of gene therapy. The company specializes in developing gene therapy treatments specifically for advanced coronary artery disease, a severe condition that affects the heart's blood vessels. XyloCor's innovative approach is rooted in proprietary gene therapy technologies developed in collaboration with Weill Cornell Medical College.
The primary clients of XyloCor are patients with advanced coronary artery disease, a demographic that often has limited treatment options. The company operates within the biotechnology and healthcare markets, focusing on cutting-edge medical research and development.
XyloCor's business model revolves around the research, development, and eventual commercialization of gene therapy products. Revenue is generated through a combination of research grants, partnerships with medical institutions, and future sales of their gene therapy treatments once they receive regulatory approval.
By addressing a critical unmet need in cardiovascular health, XyloCor aims to provide a transformative impact on patient outcomes.
Keywords: gene therapy, cardiovascular disease, coronary artery disease, biotechnology, healthcare, medical research, proprietary technologies, Weill Cornell, patient outcomes, advanced treatments.